VGXI Gears To Support Production Of New Coronavirus Vaccine
Initial Manufacturing Of Inovio/Advaccine Candidate
VGXI, a contract manufacturer of plasmid DNA and US subsidiary of Korea’s GeneOne Life Science, joins in the R&D efforts for a DNA vaccine against the new Wuhan coronavirus, using its proprietary manufacturing platform as part of a new agreement with Inovio.
You may also be interested in...
Codagenix, a company backed by Novartis, Merck and the Bill & Melinda Gates Foundation, has tied up with India’s Serum Institute to develop a vaccine against SARS-CoV-2, joining a heated race against the dreaded COVID-19 outbreak.
The pharma major is providing its adjuvant system, designed to enhance the body’s immune response, to help the Coalition for Epidemic Preparedness Innovations' efforts to accelerate the creation of a vaccine for the coronavirus strain that broke out in China and has spread to 24 countries.